Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Better Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BTTX
Over the counter
8731
https://www.bettertx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Better Therapeutics Inc
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
- Mar 14th, 2024 1:38 pm
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
- Mar 5th, 2024 2:25 pm
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
- Mar 4th, 2024 2:25 pm
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
- Mar 1st, 2024 2:00 pm
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
- Feb 20th, 2024 2:25 pm
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
- Feb 6th, 2024 2:43 pm
David Perry Bought 8.6% More Shares In Better Therapeutics
- Jan 18th, 2024 12:06 pm
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
- Jan 17th, 2024 2:28 pm
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
- Jan 4th, 2024 7:00 pm
Better Therapeutics Insiders Added US$6.57m Of Stock To Their Holdings
- Jan 3rd, 2024 5:04 pm
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
- Jan 2nd, 2024 12:45 pm
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
- Nov 28th, 2023 12:45 pm
Frost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership Award
- Nov 14th, 2023 12:00 pm
Better Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 12:00 pm
Better Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023
- Nov 8th, 2023 12:30 pm
Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference
- Oct 26th, 2023 11:55 am
Better Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 Diabetes
- Oct 16th, 2023 11:55 am
Better Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes
- Oct 11th, 2023 11:55 am
Better Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep Advances
- Oct 5th, 2023 11:45 am
Better Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes
- Sep 28th, 2023 8:16 pm
Scroll